Hint mode is switched on Switch off
For swift navigation between sections

TetraLogic
LEI 549300X6IO859O0VG962

Organization name
TetraLogic Pharmaceuticals Corporation
Country name
USA
Country of registration
USA
Industry
Miscellaneous Healthcare: Products and Services
Public debt
-
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Quotes

Request sent
Access denied
Quotes provided by information providers are indicative in nature

Profile

TetraLogic Pharmaceuticals Corporation (TetraLogic) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing novel small molecule therapeutics that mimic Second Mitochondrial Activator of Caspases (SMAC)-mimetics, and are designed to cause or enable abnormal cells that are resistant to the body's immune system to self-destruct. Birinapant, its clinical-stage product candidate, is being tested in Phase I and Phase II oncology clinical trials for multiple solid tumors and hematological malignancies. The Company’s clinical trials of birinapant have enrolled over 275 subjects. In April 2014,Tetralogic Pharmaceuticals Corp acquired the entire share capital of Shape Pharmaceutical Inc.

Awards

Documentation

IFRS/US GAAP reports

2016
2015
2014
Show more Hide
Authorization required
You need to request access

Stocks

Latest issues

Public debt by currencies

Codes

  • LEI
    549300X6IO859O0VG962
  • NACE
    *** ***
  • NAICS
    *** ***
  • CIK
    0001361248
Registration is required to get access.